Tango Therapeutics Q2 2024 GAAP EPS $(0.24) Beats $(0.33) Estimate, Sales $19.875M Beat $7.423M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tango Therapeutics reported its Q2 2024 financial results, with a GAAP EPS of $(0.24), beating the estimate of $(0.33). The company also reported sales of $19.875 million, surpassing the estimated $7.423 million.
August 07, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics reported better-than-expected Q2 2024 results, with a GAAP EPS of $(0.24) beating the $(0.33) estimate and sales of $19.875 million surpassing the $7.423 million estimate.
The better-than-expected earnings and sales figures are likely to positively impact Tango Therapeutics' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100